drugset
drugset / Trial / NCT05802173

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

NCT05802173 ↗

Phase 2 Completed 71 enrolled Technoderma Medicines Inc. Therapeutics, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

Randomized, double-blind, vehicle-controlled, parallel group, multi-dose study of TDM-105795 in male subjects with androgenetic alopecia

Timeline

Start
2023-03-06
Primary completion
2023-11-08
Completion
2024-01-29

Drugs

EvaluationDrugModalityDoseRoute
Subject TDM-105795 Unknown 0.0025 % Topical
Subject TDM-105795 Unknown 0.02 % Topical

Indications

androgenetic alopecia